Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BMS-986231 Formulations in Healthy Participants
NCT03891108Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cimlanod in heart failure (HF) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Plasma Concentration, Average Concentration Over a Dosing Interval and 8 more. Started Feb 2019; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03891108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891108.